A Study of ASP2074 in Adults With Solid Tumors
NCT05646797 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2025-10-20
Summary
ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. This information will help find a suitable dose and check for potential medical problems from the treatment. People in this study will be adults with metastatic or locally advanced solid tumors. Metastatic means the cancer has spread to other parts of the body. They will have been previously treated with all available standard therapies and they may no longer be benefitting from further treatment.
There are 2 main aims of this study. The first is to learn if people with certain solid tumors have any medical problems after receiving different doses of ASP2074. The second is to find a suitable dose of ASP2074 to use in future studies.
This study will be in 2 parts.
In Part 1, different small groups of people will receive lower or higher doses of ASP2074. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP2074 to use in Part 2 of the study. The first group will receive the lowest dose of ASP2074. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP2074. The panel will do this for each group until all groups have taken ASP2074 or until suitable doses have been selected for Part 2.
In Part 2, other different small groups of people will receive ASP2074 with the most suitable doses worked out from Part 1. This will help find a more accurate dose of ASP2074 to use in future studies.
ASP2074 will be given as an infusion on the first day of each treatment cycle. The people in this study will have treatment cycles until: they have medical problems from the treatment; their cancer gets worse; they start other cancer treatment; they ask to stop treatment; or they do not come back for treatment.
People will visit the clinic on certain days during their treatment, with extra visits during the first 2 cycles of treatment. During these visits, the study doctors will check for any medical problems from ASP2074. At some visits, other checks will include a medical examination, laboratory tests and vital signs. Vital signs include temperature, pulse, and blood pressure. Also, blood and urine samples will be taken. Electrocardiograms will be done to check the heart rhythm during the study. Tumor samples will be taken during certain visits before treatment begins, during treatment, and when treatment has finished.
People will visit the clinic within 7 days after stopping treatment. The study doctors will check for any medical problems from ASP2074. Other checks will include a medical examination, laboratory tests and vital signs. Then, people may visit the clinic at 30 days after stopping treatment. Thirty and 90 days after the last dose, the study doctors will check for any medical problems from ASP2074. People will have their vital signs checked and have some laboratory tests. After this, people will continue to visit the clinic every 6 weeks. This is to check the condition of their cancer. They will do this until their cancer is worse, they start other cancer treatment, they ask to leave the study, or they do not come back for treatment. Then, the study doctors will call every 12 weeks for up to 1 year or until that person asks to leave the study, the study is stopped, or the person cannot be reached.
Conditions
Interventions
- DRUG
-
ASP2074
intravenous (IV) infusion
Sponsors & Collaborators
-
Astellas Pharma Global Development, Inc.
lead INDUSTRY
Principal Investigators
-
Senior Medical Director · Astellas Pharma Global Development, Inc.
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-28
- Primary Completion
- 2024-10-17
- Completion
- 2024-10-17
- FDA Drug
- Yes
Countries
- United States
- Japan
Study Locations
More Related Trials
-
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
NCT06681870 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
NCT03945253 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of DS-1471a In Subjects With Advanced Solid Tumors
NCT06074705 ·Status: TERMINATED ·Phase: PHASE1
-
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT03260322 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ASP3082 in Adults With Advanced Solid Tumors
NCT05382559 ·Status: RECRUITING ·Phase: PHASE1
-
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00077077 ·Status: COMPLETED ·Phase: PHASE1
-
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
NCT05631327 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795 ·Status: TERMINATED ·Phase: PHASE1
-
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02503709 ·Status: COMPLETED ·Phase: PHASE1
-
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
NCT04939701 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
NCT05605522 ·Status: TERMINATED ·Phase: PHASE1
-
BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment
NCT00005611 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
NCT05028478 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004 ·Status: RECRUITING ·Phase: PHASE1
-
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
NCT04746612 ·Status: TERMINATED ·Phase: PHASE1
-
Study of AS1411 in Advanced Solid Tumours
NCT00881244 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
NCT03954067 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
NCT00276913 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
NCT00404521 ·Status: TERMINATED ·Phase: PHASE1
-
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
NCT03471286 ·Status: TERMINATED ·Phase: PHASE1